3-氯-4-氟苯肼盐酸盐 | 175135-74-7

• 物质功能分类: 化学试剂 - 有机试剂 - 肼
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯-4-氟苯肼盐酸盐
• 中文别名: 3-氯-4-氟苯肼盐酸
• 英文名称: (3-chloro-4-fluorophenyl)hydrazine hydrochloride
• 英文别名: 3-Chloro-4-fluorophenylhydrazine hydrochloride；(3-chloro-4-fluorophenyl)hydrazine;hydrochloride
• CAS: 175135-74-7
• 化学式: C₆H₆ClFN₂*ClH
• mdl: MFCD00052267
• 分子量: 197.039
• InChiKey: DWCDDXINAZHRLK-UHFFFAOYSA-N

物化性质

• 熔点：
  211 °C
• 溶解度：
  可溶于DMSO（轻微）、甲醇（轻微、加热）
• 稳定性/保质期：
  避氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  2.11
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  39.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S22,S24/25
• 危险类别码：
  R20/21/22
• 海关编码：
  29280000
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  保存方法：应存放在密闭、阴凉、通风良好的干燥处。

SDS

Name:	1-(3-Chloro-4-fluorophenyl)hydrazine hydrochloride 97% Material Safety Data Sheet
Synonym:
CAS:	175135-74-7

Section 1 - Chemical Product MSDS Name:1-(3-Chloro-4-fluorophenyl)hydrazine hydrochloride 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175135-74-7	1-(3-Chloro-4-fluorophenyl)hydrazine h	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175135-74-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white - tan
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 211 - 212 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H7Cl2FN2
Molecular Weight: 197

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, bases.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175135-74-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(3-Chloro-4-fluorophenyl)hydrazine hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 175135-74-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175135-74-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175135-74-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

3-氯-4-氟苯肼盐酸盐可作为医药合成中间体，用于制备2-(3-氯-4-氟苯基)-6-(3-(4-(6-氟苯[d]异恶唑-3-基)哌啶-1-基)丙氧基)哒嗪-3(2H)-酮。该药物可用于预防或治疗精神类疾病，如精神分裂症。

反应信息

• 作为反应物：
  描述：

  3-氯-4-氟苯肼盐酸盐 以 concentrated acetic acid 、 乙醇 、 乙酸乙酯 为溶剂， 生成 Ethyl 1-(3-chloro-4-fluorophenyl)-5-(3-chloro-5-fluorophenyl)-1H-pyrazole-3-carboxylate
  参考文献：
  名称：

  Solid dispersion comprising an anti-HIV agent

  摘要：

  公开号：

  EP2295038B1
• 作为产物：
  描述：

  3-氯-4-氟苯胺 在 盐酸 、 sodium nitrite 、 tin(II) chloride dihdyrate 作用下， 以 水 为溶剂， 反应 0.75h， 以90%的产率得到3-氯-4-氟苯肼盐酸盐
  参考文献：
  名称：

  吲哚类衍生物及其医药用途

  摘要：

  本发明公开了一种具有FABP4/5抑制活性的吲哚类化合物及其制备方法和医药用途，其为结构式如式I所示的化合物、其药学上可接受的盐或酯或溶剂化物。本发明的式I化合物是新型FABP4/5抑制剂，可用于制备预防或治疗FABP4/5相关疾病的药物。

  公开号：

  CN112028815A
• 作为试剂：
  描述：

  lithium;(Z)-1-(3-chloro-5-fluorophenyl)-4-ethoxy-3,4-dioxobut-1-en-1-olate 、 3-氯-4-氟苯肼盐酸盐 在 3-氯-4-氟苯肼盐酸盐 作用下， 以76的产率得到Ethyl 1-(3-chloro-4-fluorophenyl)-5-(3-chloro-5-fluorophenyl)-1H-pyrazole-3-carboxylate
  参考文献：
  名称：

  SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE

  摘要：

  本发明涉及一种新型的取代（吡唑基羰基）咪唑啉酮，其制备方法，其用于治疗和/或预防疾病的用途，以及其用于制造用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防人类和/或动物的逆转录病毒性疾病。

  公开号：

  US20110124618A1

文献信息

• [EN] NEW CRTh2 ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES DE CRTH2
  申请人：ALMIRALL SA

  公开号：WO2013010881A1

  公开（公告）日：2013-01-24

  The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

  本发明涉及公式(I)的化合物，制备此类化合物的方法以及它们在治疗可通过CRTh2拮抗剂活性改善的病理状况或疾病中的用途。
• [EN] POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES<br/>[FR] DÉRIVÉS D'URÉE POLYAROMATIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES MUSCULAIRES
  申请人：ANAGENESIS BIOTECHNOLOGIES S A S

  公开号：WO2021013712A1

  公开（公告）日：2021-01-28

  The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

  当前的发明提供尿素衍生物，特别是具有核心结构杂环基-NH-CO-NH-芳基-O-杂环基的化合物，用于治疗、改善、延缓、治愈和/或预防与肌肉细胞和/或卫星细胞相关的疾病或症状，如杜兴氏肌肉萎缩症、贝克氏肌肉萎缩症、虚弱或肌肉萎缩症。
• [EN] NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE PROLYLCARBOXYPEPTIDASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011156220A1

  公开（公告）日：2011-12-15

  Compounds of structural formulas I-1 and I-2 are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.

  结构公式I-1和I-2的化合物是脯氨酰羧肽酶（PrCP）的抑制剂。本发明的化合物可用于预防和治疗与PrCP的酶活性相关的状况，包括异常代谢，如肥胖、糖尿病、代谢综合征、与肥胖相关的疾病以及与糖尿病相关的疾病。
• New CRTh2 antagonists.
  申请人：Almirall, S.A.

  公开号：EP2548863A1

  公开（公告）日：2013-01-23

  The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

  这项发明涉及到式(I)化合物，制备这种化合物的方法以及它们在治疗病理状况或疾病中的应用，这些病理状况或疾病对CRTh2拮抗活性有改善作用。
• 吲哚类衍生物及其医药用途
  申请人：中国药科大学

  公开号：CN112028815A

  公开（公告）日：2020-12-04

  本发明公开了一种具有FABP4/5抑制活性的吲哚类化合物及其制备方法和医药用途，其为结构式如式I所示的化合物、其药学上可接受的盐或酯或溶剂化物。本发明的式I化合物是新型FABP4/5抑制剂，可用于制备预防或治疗FABP4/5相关疾病的药物。